Preliminary evaluation of prostate‐targeted radiotherapy using (131)I‐MIP‐1095 in combination with radiosensitising chemotherapeutic drugs

OBJECTIVES: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy. (131)I‐MIP‐1095 is a recently developed prostate‐specific membrane antigen (PSMA)‐targeting, small molecular weight radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesson, Mathias, Rae, Colin, Nixon, Colin, Babich, John W., Mairs, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Molecular and Clinical Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298040/
https://www.ncbi.nlm.nih.gov/pubmed/27139157
http://dx.doi.org/10.1111/jphp.12558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298040/
https://www.ncbi.nlm.nih.gov/pubmed/27139157
http://dx.doi.org/10.1111/jphp.12558

Ejemplares similares